Over a hundred pharmaceutical companies have released their performance forecasts for the first half of the year, with the main themes being the international expansion of innovative drugs and the realization of value.

According to Wind data, as of August 3, a total of 104 pharmaceutical and biotechnology companies listed on the A-shares have disclosed their performance forecasts for the first half of 2026. In terms of expected net profit limits, 58 companies anticipate an increase in net profit attributable to shareholders in the first half of this year, with 28 of them expecting a year-on-year growth of over 100%. Analysts believe that the current focus has shifted to the overseas commercialization of innovative drugs and the realization of value, with the market's requirements for the quality of licensed cooperation becoming increasingly stringent. There is greater emphasis on the substance of upfront payments, the strength of partners, and the robustness of clinical data. Pharmaceutical companies that can achieve overseas commercialization through leading products and possess sustainable innovation capabilities will be more favored by the market.